An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.

Eli Lilly and Company1,131 enrolled

Overview

The primary objective of this study is to assess the proportion of schizophrenic patients and the proportion of bipolar patients who discontinue olanzapine within 12 months of treatment in outpatient, ambulatory or community settings

Study Type

OBSERVATIONAL

Enrollment

1,131

Conditions

Schizophrenia Bipolar Disorder

Interventions

olanzapineDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients suffering from schizophrenic or schizoaffective disorders based on the disease diagnostic criteria DSM IV and being prescribed olanzapine during the 45 preceding days. * patients suffering from bipolar disorders based on the disease diagnostic criteria DSM IV and being prescribed olanzapine during the 45 preceding days for one of the following: * moderate or severe manic episode * relapse prevention in patients with bipolar disorder Exclusion Criteria: * current treatment with any investigational drug or procedure at entry or during the whole study * hypersensitivity to olanzapine * patients with known narrow angle glaucoma risk

Locations (3)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Paris, France

Bad Homburg, Germany

Thessaloniki, Greece

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.